These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28176362)

  • 1. Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.
    Kamal MA; Smith PF; Chaiyakunapruk N; Wu DBC; Pratoomsoot C; Lee KKC; Chong HY; Nelson RE; Nieforth K; Dall G; Toovey S; Kong DCM; Kamauu A; Kirkpatrick CM; Rayner CR
    Br J Clin Pharmacol; 2017 Jul; 83(7):1580-1594. PubMed ID: 28176362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.
    Wu DBC; Chaiyakunapruk N; Pratoomsoot C; Lee KKC; Chong HY; Nelson RE; Smith PF; Kirkpatrick CM; Kamal MA; Nieforth K; Dall G; Toovey S; Kong DCM; Kamauu A; Rayner CR
    Epidemiol Infect; 2018 Mar; 146(4):496-507. PubMed ID: 29446343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
    Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
    Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
    Shen K; Xiong T; Tan SC; Wu J
    PLoS One; 2016; 11(4):e0153664. PubMed ID: 27082431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.
    Postma MJ; Novak A; Scheijbeler HW; Gyldmark M; van Genugten ML; Wilschut JC
    Pharmacoeconomics; 2007; 25(6):497-509. PubMed ID: 17523754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.
    Talbird SE; Brogan AJ; Winiarski AP; Sander B
    Am J Health Syst Pharm; 2009 Mar; 66(5):469-80. PubMed ID: 19233995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1.
    Renaud C; Kuypers J; Englund JA
    J Clin Virol; 2011 Oct; 52(2):70-8. PubMed ID: 21684202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
    Turner D; Wailoo A; Nicholson K; Cooper N; Sutton A; Abrams K
    Health Technol Assess; 2003; 7(35):iii-iv, xi-xiii, 1-170. PubMed ID: 14609480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada.
    O'Brien BJ; Goeree R; Blackhouse G; Smieja M; Loeb M
    Value Health; 2003; 6(2):116-25. PubMed ID: 12641862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan.
    Nagase H; Moriwaki K; Kamae M; Yanagisawa S; Kamae I
    Value Health; 2009; 12 Suppl 3():S62-5. PubMed ID: 20586984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
    Talbird SE; Brogan AJ; Winiarski AP
    Am J Prev Med; 2009 Nov; 37(5):381-8. PubMed ID: 19840692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.
    Sander B; Hayden FG; Gyldmark M; Garrison LP
    Pharmacoeconomics; 2006; 24(4):373-86. PubMed ID: 16605283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness.
    Venkatesan S; Carias C; Biggerstaff M; Campbell AP; Nguyen-Van-Tam JS; Kahn E; Myles PR; Meltzer MI
    J Public Health (Oxf); 2019 Jun; 41(2):379-390. PubMed ID: 29955851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of oseltamivir treatment for children with uncomplicated seasonal influenza.
    Lavelle TA; Uyeki TM; Prosser LA
    J Pediatr; 2012 Jan; 160(1):67-73.e6. PubMed ID: 21917267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.
    Tappenden P; Jackson R; Cooper K; Rees A; Simpson E; Read R; Nicholson K
    Health Technol Assess; 2009 Feb; 13(11):iii, ix-xii, 1-246. PubMed ID: 19215705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.
    Rothberg MB; Bellantonio S; Rose DN
    Ann Intern Med; 2003 Sep; 139(5 Pt 1):321-9. PubMed ID: 12965940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes.
    Postma MJ; Beardsworth P; Wilschut JC
    J Med Econ; 2008; 11(4):743-68. PubMed ID: 19450079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of "test" versus "treat" patients hospitalized with suspected influenza in Hong Kong.
    You JH; Chan ES; Leung MY; Ip M; Lee NL
    PLoS One; 2012; 7(3):e33123. PubMed ID: 22479363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.
    Lugnér AK; Postma MJ
    Eur J Public Health; 2009 Oct; 19(5):516-20. PubMed ID: 19692550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of oseltamivir in the treatment and prevention of influenza in children.
    Whitley RJ
    Expert Opin Drug Metab Toxicol; 2007 Oct; 3(5):755-67. PubMed ID: 17916060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.